MBX Biosciences, Inc.

📍 Carmel, United States🗓 Founded 2019👥 18 employees💰 Last funded Jul 2020
Biotechnology Research🌐 mbxbio.com
Website LinkedIn
MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs™). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company’s lead product candidate, MBX 2109 for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. Members of MBX’s leadership team have collaborated over several decades on the discovery, development, and commercialization of highly successful endocrine therapeutics including Forteo® and Humalog®. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates and OrbiMed.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in MBX Biosciences, Inc.?
MBX Biosciences, Inc. has 1 investors on record on gritt.io, including 1 early-stage backers.
When did MBX Biosciences, Inc. last raise funding?
The most recent investment in MBX Biosciences, Inc. recorded on gritt.io was in July 2020.
When was MBX Biosciences, Inc. founded?
MBX Biosciences, Inc. was founded in 2019.
What industry is MBX Biosciences, Inc. in?
MBX Biosciences, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is MBX Biosciences, Inc. based?
MBX Biosciences, Inc. is headquartered in Carmel, United States.